Companies › Integrative Skin Science and Research
2 active drug programs in 2 registered trials: 2 Phase 4; Immunology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Sarecycline Tetracycline antibiotic with preferential activity against Propionibacterium acnes | – | Phase 4 | Acne Vulgaris | Apr 2027 |
| Roflumilast Phosphodiesterase 4 inhibitor | PDE4A, PDE4D, PDE4B, PDE4C | Phase 4 | ITCH | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07544251 | Sarecycline | Phase 4 | Acne Vulgaris | Immunology | Apr 2027 |
| NCT07560618 | Roflumilast | Phase 4 | ITCH | Immunology | Aug 2027 |
Palisade Bio Ganzhou Hemay Pharmaceutical Pharvaris Netherlands AUG Therapeutics Lynk Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.